Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
11.40
+0.41 (3.73%)
At close: Jun 8, 2026, 4:00 PM EDT
11.35
-0.05 (-0.44%)
After-hours: Jun 8, 2026, 4:10 PM EDT
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
130.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Alps Group | 93 |
| Agenus | 81 |
| Alpha Cognition | 71 |
| Connect Biopharma Holdings | 64 |
| Genelux | 26 |
| TuHURA Biosciences | 22 |
| AN2 Therapeutics | 21 |
KZIA News
- 6 days ago - Kazia Therapeutics appoints James Levine as CFO - TheFly
- 6 days ago - Kazia Therapeutics Appoints James Levine as Chief Financial Officer - PRNewsWire
- 13 days ago - Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 7 weeks ago - Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer - TheFly
- 7 weeks ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
- 7 weeks ago - Kazia Therapeutics initiated with a Buy at Laidlaw - TheFly
- 2 months ago - Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer - TheFly
- 2 months ago - Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - PRNewsWire